SEEBRI Drug Patent Profile

When do Seebri patents expire, and what generic alternatives are available?

Seebri is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.

This drug has ninety-nine patent family members in thirty-two countries.

The generic ingredient in SEEBRI is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-five suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Seebri

A generic version of SEEBRI was approved as glycopyrrolate by AM REGENT on July 23^rd, 1986.

Summary for SEEBRI

International Patents:	99
US Patents:	2
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	113
Clinical Trials:	3
Patent Applications:	3,890
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for SEEBRI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for SEEBRI
DailyMed Link:	SEEBRI at DailyMed

See drug prices for SEEBRI

Recent Clinical Trials for SEEBRI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Saskatchewan	Phase 4
Sunovion Respiratory Development Inc.	Phase 1

See all SEEBRI clinical trials

US Patents and Regulatory Information for SEEBRI

SEEBRI is protected by two US patents.

Patents protecting SEEBRI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015		DISCN	Yes	No			Y
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015		DISCN	Yes	No			Y

Expired US Patents for SEEBRI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015
Novartis	SEEBRI	glycopyrrolate	POWDER;INHALATION	207923-001	Oct 29, 2015

International Patents for SEEBRI

See the table below for patents covering SEEBRI around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1112389
Ukraine	61051	POWDER FOR USE IN DRY POWDER INHALER (VARIANTS), METHOD FOR PRODUCING POWDER (VARIANTS), PARTICLES USED IN POWDER (VARIANTS), METHOD FOR THEIR MANUFACTURE AND ADDITIVE MATERIAL
World Intellectual Property Organization (WIPO)	0178693
Germany	602005027064
South Korea	101170187

Supplementary Protection Certificates for SEEBRI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	SPC/GB21/029	United Kingdom		PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210
1267866	C300583	Netherlands		PRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
1267866	122013000029	Germany		PRODUCT NAME: GLYKOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
2435025	2019C/532	Belgium		PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220
1267866	493	Finland